新西兰拨款604M万美元,用于扩大癌症、心脏病和其他疾病的药物供应。 New Zealand allocates $604M to expand drug access for cancer, heart failure, and other conditions.

新西兰政府又拨款6.04亿美元给该国的医药供资机构药剂师,这大大促进了药品的获取。 New Zealand's government has allocated an additional $604 million to Pharmac, the country's pharmaceutical funding agency, significantly boosting medication access. 这笔资金将使癌症患者、慢性心脏病患者和ADHD患者受益,并提供家庭堕胎有效性测试工具包。 The funding will benefit patients with cancer, chronic heart failure, and ADHD, as well as provide home test kits for abortion effectiveness. 约112名癌症患者将获得Lenvatinib治疗,18 000名心脏病患者将受益于新的治疗,到2029年,每年将增至33 000人。 About 112 cancer patients will access Lenvatinib, while 18,000 heart failure patients will benefit from new treatments, growing to 33,000 annually by 2029. 这项投资旨在加强新西兰的保健系统。 The investment aims to enhance New Zealand's healthcare system.